Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Development of new CF gene therapy gets $320K NIH grant

Genexys Biomed has been awarded a $320,000 grant to advance the development of a novel gene therapy for cystic fibrosis (CF). The small business innovation research grant was given by the National Heart, Lung, and Blood Institute, a branch of the National Institutes of Health. The “grant is a…

FDA decision on vanza triple, new CFTR modulator, due by Jan. 2

Authorities in the U.S. and Europe are reviewing applications from Vertex Pharmaceuticals seeking approval of the company’s novel CFTR modulator triple combination, vanzacaftor, tezacaftor and deutivacaftor.  Vertex is asking that the vanza combo be approved for people with cystic fibrosis (CF) ages 6 and older who carry…

Bacterial communities show patterns in pulmonary exacerbation

During pulmonary exacerbation in cystic fibrosis (CF), bacterial communities in the lungs tend to change in one of two general patterns, and better understanding these patterns may help predict how patients will respond to antibiotic treatments. That’s according to the study, “Microbial community organization designates distinct…

Nanite, Saliogen teaming up to develop genetic medicine for CF

Two Massachusetts-based companies, Nanite and Saliogen Therapeutics, are teaming up on a new research project that aims to create a genetic medicine with the potential to treat cystic fibrosis (CF). “Nanite’s relationship with SalioGen is consequential in discovering safe polymeric nanoparticles for a transformative treatment for CF,”…

Phage therapies found to induce individualized antiviral response

Phage therapy, a promising strategy for treating antibiotic-resistant lung infections that’s currently in clinical trials, can trigger the release of inflammatory signaling molecules from human lung cells, with different types of phages triggering a different set of signaling molecules. That’s according to a study, “Lytic bacteriophages induce…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.